CD80 and neoplasm: These results suggest that PD-1/CD80+ sEVs potentially contribute to the increased circulating PD-L1+ sEV levels and the decreased tumour cell PD-L1 expression levels, which may be closely associated with resistance to anti-PD-1 therapy.